Announcements Trials

Browse Landscape

Phase

Phase 3 2 Phase 2 2 Phase NA 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 10 Squamous Cell Carcinoma of Head and Neck 8 Neoplasms 6 Head and Neck Neoplasms 6 Prostatic Neoplasms 5 Oropharyngeal Neoplasms 5 Lung Neoplasms 5 Urinary Bladder Neoplasms 4 Stomach Neoplasms 4 Neoplasm Metastasis 4 Myasthenia Gravis 4 Lymphoma, Large B-Cell, Diffuse 4 Cholangiocarcinoma 4 Recurrence 3 Pancreatic Neoplasms 3 Ovarian Neoplasms 3 Mouth Neoplasms 3 Leukemia, Myeloid, Acute 3 Laryngeal Neoplasms 3 Hypopharyngeal Neoplasms 3 Glioblastoma 3 Fatigue 3 Endometrial Neoplasms 3 Carcinoma 3 Breast Neoplasms 3 Weight Loss 2 Uterine Cervical Neoplasms 2 Thyroid Neoplasms 2 Nasopharyngeal Carcinoma 2 Melanoma 2

Interventions

tucatinib 1 Trastuzumab 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × HER2-positive Breast Cancer × 30 days × Clear all

NCT07413939 2026-05-11

BREnnA

Hoffmann-La Roche

Phase 2/3 Recruiting

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡